Tesamorelin
A stabilized GHRH analog administered by subcutaneous injection.
What this compound is.
Tesamorelin is a stabilized analog of growth-hormone-releasing hormone. Structural modifications are intended to extend its activity relative to native GHRH, and it too acts on the pituitary rather than supplying growth hormone directly.
It has been the subject of controlled clinical study, which is part of why it is discussed in a more specific clinical context than some other compounds in this class.
How it has been studied.
Neutral notes on how this compound has been studied. These are not claims of safety or effectiveness, and not medical advice.
Studied clinically in the context of visceral adipose (deep abdominal fat) tissue.
Examined within the broader body of growth-hormone-axis research.
Reviewed for its stability and duration of action among GHRH analogs.
Format, and what a provider weighs.
Prescribed formulations are typically administered by subcutaneous injection. Form and suitability are a provider's decision — nothing here is a recommendation, a protocol, or a dose.
- A provider evaluates your metabolic and endocrine history before considering a prescription.
- Not appropriate during pregnancy or while breastfeeding.
- Suitability, formulation, and availability are determined by the provider and vary by state.
Tesamorelin cannot be purchased directly on this site. It is available only after a licensed provider evaluates your intake and determines that treatment is clinically appropriate, and it is dispensed by a licensed compounding pharmacy. Eligibility is never guaranteed, and availability varies by state. See how it works and our approach to care.